Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QingyiHuaji Optimized Formula + Chemotherapy in Advanced Pancreatic Cancer
NCT05840341Phase 3Completed
- Sponsor
- Fudan University
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Qingyi Huaji in pancreatic ductal adenocarcinoma (PDAC), sponsored by Fudan University. Started Apr 2023; status: completed.
02
Drugs
Qingyi Huaji
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05840341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840341.